CorVel Corporation — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended June 30, 2011 (CorVel’s first fiscal quarter of fiscal 2012), compared with the quarter ended June 30, 2010. This conflicts with the request metadata “2010 Q1.”
Business context and reporting period
CorVel provides medical cost-containment and managed-care services, primarily to workers’ compensation and auto-insurance payors. Its services are grouped as Patient Management and Network Solutions; the company reports one operating segment. The filing is unaudited and was filed August 5, 2011.
Financial performance and liquidity
| Metric | Three months ended June 30, 2010 | Three months ended June 30, 2011 | Change |
|---|---|---|---|
| Revenue | $91.5 million | $102.3 million | +11.8% |
| Gross profit | $23.8 million | $25.5 million | +7.3% |
| Gross margin | 26.0% | 25.0% | −1.0 percentage point |
| Income before tax | $12.3 million | $13.2 million | +7.6% |
| Net income | $7.8 million | $8.2 million | +5.6% |
| Diluted EPS | $0.64 | $0.70 | +9.4% |
| Operating cash flow | $10.9 million | $15.2 million | +$4.3 million |
- Revenue grew in both service lines: Patient Management rose 11.5% to $48.3 million, and Network Solutions rose 12.0% to $54.0 million. Management attributed Patient Management growth to greater service levels for existing TPA customers, and Network Solutions growth mainly to pharmacy and directed-care utilization.
- Cost of revenue rose 13.4%, faster than revenue, largely reflecting higher pharmacy and directed-care demand. Direct pharmacy costs increased from $6 million to $10 million. Gross margin declined to 25.0%.
- General and administrative expense increased 7.0% to $12.3 million, primarily from systems costs, which rose from $6.3 million to $6.8 million. Pretax margin was 13.0%, versus 13.5%; the effective tax rate was approximately 38%, versus 37%.
- At June 30, cash and cash equivalents were $17.6 million; current assets were $86.9 million, current liabilities $57.1 million, and working capital $29.8 million. Total assets were $172.5 million and stockholders’ equity $105.6 million.
- Operating cash flow was $15.2 million; investing cash outflow was $7.0 million, principally property and equipment purchases, including capitalized software development; financing cash outflow was $2.9 million, including $3.7 million of treasury-stock purchases.
- No debt was outstanding. A $10 million revolving facility was available, with no revolver borrowings; the agreement was due to expire in September 2011, and management expected renewal. The filing gives conflicting letters-of-credit amounts: $6.3 million in Note G and $8.0 million in MD&A.
Material changes, outlook, risks and unusual items
- Share repurchases reduced weighted-average diluted shares 3.3% year over year and supported EPS growth. CorVel repurchased 77,530 shares for $3.7 million in the quarter; it reported an additional 46,090 shares purchased for $2.2 million through August 3, 2011.
- Management said cash and anticipated internally generated funds should cover obligations, planned share repurchases, new services and development for at least the next 12 months. No specific revenue or earnings guidance was provided. Management expected software-development spending to continue and expected to renew the credit facility.
- Operating cash-flow growth partly reflected higher accounts and taxes payable because the quarter’s tax payment was not due until mid-July. Capital spending increased year over year, primarily due to software development and capitalization.
- A Louisiana class-action settlement for $9 million was accrued as a pretax charge in the March 2011 quarter, not the quarter covered here. CorVel executed a definitive settlement agreement and deposited $9 million into escrow on July 6, 2011. Preliminary court approval had been granted, but final approval remained contingent on the class process and a November 4, 2011 hearing. The settlement was not an admission of liability.
- The Illinois Roche class-action settlement had received final court approval; initial payments to class members were sent July 18, 2011. The filing says a $2.8 million liability had been accrued in the September 2010 quarter.
- Key stated risks include litigation and professional-liability exposure, regulation, competition and pricing pressure, customer loss or insourcing, declining workers’ compensation claims, staffing costs, and technology, data-security and systems risks. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended reporting period: the filing covers June 30, 2011, not 2010 Q1.
- Check the final outcome and payment mechanics of the $9 million Louisiana settlement, including court approval, objections and opt-outs; verify whether any insurance proceeds were assigned or recovered.
- Reconcile the filing’s inconsistent $6.3 million and $8.0 million letters-of-credit disclosures and confirm renewal and terms of the $10 million credit facility after September 2011.
- Monitor whether pharmacy and directed-care growth remains profitable, given cost growth outpaced revenue and gross margin declined.
- Assess ongoing share repurchases and capitalized software spending against operating cash generation and the company’s stated liquidity needs.